|
業務類別
|
Biotechnology |
|
業務概覽
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD). |
| 公司地址
| 890 Winter Street, Suite 200, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 781 208-2466 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.upstreambio.com |
| 員工數量
| 75 |
| Mr. Michael Paul Gray, M.B.A. |
Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer |
美元 490.00K |
16/04/2026 |
| Ms. Allison Ambrose, J.D. |
Senior Vice President, General Counsel and Secretary |
-- |
16/04/2026 |
| Dr. Everett Rand Sutherland, M.D. |
Chief Executive Officer and Director |
美元 650.00K |
16/04/2026 |
| Dr. Adam Houghton, PhD |
Chief Business Officer |
-- |
16/04/2026 |
| Dr. Aaron Deykin, M.D. |
Chief Medical Officer and Head, Research and Development |
美元 515.00K |
16/04/2026 |
|
|
| Dr. Marcella Kuhlman Ruddy, M.D.,M.S. |
Independent Director |
16/04/2026 |
| Mr. Erez Chimovits, M.B.A.,M.Sc. |
Independent Director |
16/04/2026 |
| Dr. Everett Rand Sutherland, M.D. |
Chief Executive Officer and Director |
16/04/2026 |
| Dr. H. Edward Fleming, Jr,M.D. |
Independent Director |
16/04/2026 |
| Ms. Daniella Beckman |
Independent Director |
16/04/2026 |
| Mr. Ronald C. Renaud, Jr,M.B.A. |
Non-Executive Chairman of The Board |
16/04/2026 |
| Dr. Liam Ratcliffe, M.B.,M.B.A.,PhD |
Independent Director |
16/04/2026 |
|
|
|
|
